Clinical Trial Update: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating selinexor in combination with HAD or CAG regimens for relapsed or refractory acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• XPOVIO (selinexor)

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Status: RECRUITING